PMID- 25174723
OWN - NLM
STAT- MEDLINE
DCOM- 20150601
LR  - 20211021
IS  - 1520-6017 (Electronic)
IS  - 0022-3549 (Print)
IS  - 0022-3549 (Linking)
VI  - 103
IP  - 10
DP  - 2014 Oct
TI  - Effect of 3,4-methylenedioxymethamphetamine on the toxicokinetics and sedative 
      effects of the drug of abuse, gamma-hydroxybutyric acid.
PG  - 3310-5
LID - 10.1002/jps.24122 [doi]
AB  - gamma-Hydroxybutyric acid (GHB) is widely abused in combination with other club drugs 
      such as 3,4-methylenedioxymethamphetamine (MDMA). The objectives of this study 
      were to characterize the effects of MDMA on GHB toxicokinetics/toxicodynamics 
      (TK/TD) and evaluate the use of monocarboxylate transporter (MCT) inhibition as a 
      potential treatment strategy for GHB overdose when GHB is abused with MDMA. Rats 
      were administered GHB 400 mg/kg i.v. alone or with MDMA (5 mg/kg i.v). Effects of 
      MDMA and of the MCT inhibitor, l-lactate, on GHB TK and sedative effects were 
      evaluated. The results of this study demonstrated no significant effect of MDMA 
      on GHB TK or TD. GHB plasma concentrations were unchanged, and GHB 
      concentration-effect relationships, based on plasma and brain concentrations and 
      the return-to-righting reflex (RRR), were similar in the presence and absence of 
      MDMA. l-Lactate administration resulted in a significant decrease in the sedative 
      effect (RRR) of GHB when it was coadministered with MDMA. Our results indicate 
      that MDMA does not affect the TK/TD of GHB at the doses used in this study, and 
      MCT inhibition using l-lactate, an effective overdose treatment strategy for GHB 
      alone, is also effective for GHB overdose when GHB is coingested with MDMA.
CI  - (c) 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
FAU - Vijay, Nisha
AU  - Vijay N
AD  - Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical 
      Sciences, University at Buffalo, SUNY, Buffalo, New York, 14214-8033.
FAU - Morris, Marilyn E
AU  - Morris ME
LA  - eng
GR  - R01 DA023223/DA/NIDA NIH HHS/United States
GR  - DA023223/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20140829
PL  - United States
TA  - J Pharm Sci
JT  - Journal of pharmaceutical sciences
JID - 2985195R
RN  - 0 (Hydroxybutyrates)
RN  - 0 (Hypnotics and Sedatives)
RN  - 30IW36W5B2 (4-hydroxybutyric acid)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Hydroxybutyrates/*pharmacokinetics/pharmacology/*toxicity
MH  - Hypnotics and Sedatives/*pharmacokinetics/*toxicity
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
PMC - PMC4175056
MID - NIHMS619075
OTO - NOTNLM
OT  - GHB
OT  - MDMA
OT  - blood-brain barrier
OT  - drug interaction
OT  - l-lactate
OT  - membrane transport/transporters
OT  - monocarboxylate transporters
OT  - overdose treatment
OT  - toxicokinetics
OT  - gamma-hydroxybutyrate
EDAT- 2014/09/02 06:00
MHDA- 2015/06/02 06:00
PMCR- 2015/10/01
CRDT- 2014/09/02 06:00
PHST- 2014/06/06 00:00 [received]
PHST- 2014/07/28 00:00 [revised]
PHST- 2014/07/30 00:00 [accepted]
PHST- 2014/09/02 06:00 [entrez]
PHST- 2014/09/02 06:00 [pubmed]
PHST- 2015/06/02 06:00 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - S0022-3549(15)30401-9 [pii]
AID - 10.1002/jps.24122 [doi]
PST - ppublish
SO  - J Pharm Sci. 2014 Oct;103(10):3310-5. doi: 10.1002/jps.24122. Epub 2014 Aug 29.